# Easier Injections for Multiple Myeloma Cancer Treatment

> This patent describes specific liquid mixtures (formulations) of anti-CD38 antibodies designed to be injected just under the skin for treating multiple myeloma, making administration simpler than traditional intravenous methods.

- **Patent:** US 12735501
- **Original title:** Subcutaneous formulations of daratumumab and their uses in treating multiple myeloma
- **Granted:** 2026
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical, oncology, drug_delivery

## What it does

This patent describes specific ways to create a liquid medicine (a 'formulation') containing anti-CD38 antibodies so it can be injected just under the skin ('subcutaneously'). The goal is to make it easier to give this medicine, which is used to treat a type of blood cancer called multiple myeloma. While the specific claims are not available, the invention focuses on the precise mix of ingredients that allows the anti-CD38 antibody to be delivered effectively and safely via a subcutaneous shot, rather than through a vein. For example, instead of a long infusion at a clinic, a patient could receive a quicker injection.

## What it does NOT cover

- Does not cover intravenous (IV) formulations of anti-CD38 antibodies, only those designed for subcutaneous injection.
- Does not cover formulations of other types of antibodies or drugs that are not anti-CD38 antibodies.
- Does not cover treatments for cancers other than multiple myeloma, as specified in the abstract.
- Does not cover the anti-CD38 antibody molecule itself, only its specific preparation for subcutaneous use.
- Does not cover methods of treatment that do not involve administering the specific subcutaneous formulation.

## The clever bit

The clever bit is figuring out how to make a large, complex protein like an anti-CD38 antibody stable and effective when injected in a small volume under the skin. This is challenging because such proteins often need to be highly concentrated and can be unstable or painful when administered subcutaneously, requiring specific stabilizing ingredients and precise pH levels.

## Real-world examples

1. Darzalex Faspro (daratumumab and hyaluronidase-fihj)
2. Other subcutaneous biologic drug formulations for chronic conditions
3. Oncology treatment centers using subcutaneous injections

## Why it matters

This patent aims to improve how a vital cancer drug is given to patients. Subcutaneous injections are generally quicker, less invasive, and more convenient than intravenous infusions, which often require longer visits to a clinic. This can significantly improve the patient experience and reduce the burden on healthcare facilities, making life easier for those undergoing treatment for multiple myeloma.

## Frequently asked questions

### What does Easier Injections for Multiple Myeloma Cancer Treatment cover?

This patent describes specific liquid mixtures (formulations) of anti-CD38 antibodies designed to be injected just under the skin for treating multiple myeloma, making administration simpler than traditional intravenous methods.

### When does this patent expire?

This patent is expected to expire on September 15, 2046, when the invention enters the public domain.

### What problem does this patent solve?

This patent aims to improve how a vital cancer drug is given to patients. Subcutaneous injections are generally quicker, less invasive, and more convenient than intravenous infusions, which often require longer visits to a clinic. This can significantly improve the patient experience and reduce the burden on healthcare facilities, making life easier for those undergoing treatment for multiple myeloma.

### What does this patent NOT cover?

Does not cover intravenous (IV) formulations of anti-CD38 antibodies, only those designed for subcutaneous injection.

**Full plain-English explainer:** https://patentbrief.org/patent/us/12735501/subcutaneous-formulations-of-daratumumab-and-their-uses-in-treating-multiple

**Original patent:** https://patents.google.com/patent/US12735501

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._